#2-02E.Beyond Malignancy: Re-evaluating MGUS and Clinical Significance (NEJM, 2025)

When we encounter monoclonal gammopathy of undetermined significance (MGUS) in clinical practice, how often do we consider its potential to cause significant end-organ damage beyond its risk of malignant progression? This comprehensive review article explores the pathophysiology, diagnosis, and risk stratification of MGUS, a premalignant condition present in about 5% of individuals over 5012. The paper's most critical clinical point is its emphasis that MGUS is not merely a precursor to cancer but can also cause a range of serious non-malignant disorders, collectively termed monoclonal gammopathy of clinical significance (MGCS), through direct effects of the M-protein on organs like the kidneys and nerves3.... This concept reframes MGUS as a potential etiology for unexplained systemic conditions. However, as this is a review article, clinicians must critically appraise the integrated findings, which are subject to the limitations of the original studies. Understanding the concept of MGCS is vital for physicians, as it provides a new diagnostic lens for patients with unexplained organ dysfunction and informs a more nuanced follow-up strategy for individuals diagnosed with MGUS35.

Citation: Rajkumar, S. Vincent and Shaji Kumar. Monoclonal Gammopathy of Undetermined Significance. The New England Journal of Medicine. 2025. DOI: 10.1056/NEJMra241271616.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.